Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Wall Street analysts project Hologic (HOLX) to report Q3 EPS of $1.05, a 0.9% year-over-year decline, on revenues of $1.01 billion, down 0.4%. While the consensus EPS estimate has remained unchanged, segment-level forecasts reveal varied performance, with strong growth anticipated in Skeletal Health (+33.4%) and GYN Surgical (+7.9%) offsetting notable declines in Blood Screening (-28.5%) and Breast Imaging (-10.3%). With the stock underperforming the S&P 500 recently and holding a Zacks Rank #4 (Sell), HOLX is expected to underperform the overall market in the near term.

Analysis

Wall Street consensus projects Hologic (HOLX) will report a marginal year-over-year contraction in its upcoming Q3 earnings, with revenues forecasted at $1.01 billion (-0.4%) and EPS at $1.05 (-0.9%). The stability of the consensus EPS estimate over the past 30 days suggests a lack of significant new information to alter analyst outlooks. A deeper look at segment-level projections reveals a highly divergent performance picture. Strong growth is anticipated in smaller segments, notably Skeletal Health (+33.4% YoY), Interventional Breast Solutions (+13.1%), and GYN Surgical (+7.9%). However, this strength is expected to be offset by significant declines in key areas such as Blood Screening (-28.5%) and the larger Breast Imaging segment (-10.3%). This weakness contributes to a projected 5.7% decline in the overall Total Breast Health division. The stock's recent market performance, a gain of 1.5% in the past month, has lagged the S&P 500 composite's 4.6% advance, and the stock carries a Zacks Rank #4 (Sell), indicating expectations for near-term underperformance.

Key Decisions for Investors

• Given the flat top-line forecast, negative EPS growth, and an explicit 'Sell' rating, investors should exercise caution heading into the earnings release.
• Pay close attention to the performance of the Breast Health division, as its projected 5.7% decline is a key drag on overall results; any deviation from this forecast could significantly influence the market's reaction.
• The stock's recent underperformance relative to the broader market aligns with the negative analyst sentiment, suggesting that initiating or adding to positions carries a heightened risk of continued lagging performance in the near term.
• Investors should assess whether the strong growth in Skeletal Health and GYN Surgical is sustainable and sizable enough to offset the material declines in other core business lines over the long term.